News from Absolutely PR and its clients. Absolutely PR specializes in media relations, the strategies and tactics necessary to achieve impactful editorial placements in the national/international, trade press local and social media. Follow tweets at @AbsolutelyPR or call for information 303.669.3558
"The Primavera Group will assume media relations and strategic public relations for the Colorado BioScience Association (CBSA) following the departure of Absolutely Public Relations in that role due to the retirement of Maggie Holben, Absolutely PR’s owner...
...'We’re thrilled to welcome Sarah and her associates at the Primavera Group to our CBSA team,' said April Giles, CBSA president and CEO...
...Holben said she is only “semi-retiring” from the PR business and will keep Absolutely PR open but will take on fewer projects to allow for more time for family and travel."
Kevin Smith, president and CEO of the Colorado Institute for Drug, Device and Diagnostic Development, poses at his office Aug. 29, 2011, near the Anschutz Medical Campus in Aurora. (Heather L. Smith/Aurora Sentinel)
The Primavera Group will assume the media relations and strategic public relations contract for the Colorado BioScience Association (CBSA) beginning January 5, 2015. The announcement is made by CBSA President and CEO April Giles, who says, "We’re thrilled to welcome Sarah and her associates at the Primavera Group to our CBSA team. They will be taking over from Absolutely PR’s Owner/Principal Maggie Holben who is retiring as CBSA's PR Consultant after more than ten years of service to the organization as a board member, contract PR resource and volunteer. In 2006, Absolutely PR was named CBSA Partner of the Year during the annual Awards Dinner. While we will miss Maggie, we are excited for all that will unfold under Sarah and her team’s direction going forward.”
Primavera Group is a Colorado-based brand development and integrated strategic marketing communications company that serves clients in technology, communications, business consulting and other growth industries. The team develops high-impact strategies, innovative solutions and persuasive content to communicate clients’ stories and compel audiences to action. Their client list spans established Fortune 50 companies to promising start ups.
“Our clients turn to us for crisp thinking, quick execution and our senior-level expertise. We believe the proof is in our performance, and we are proud of our 100% repeat engagement track record. We’re the firm that our clients count on time and again to generate results. In turn, our Primavera team looks forward to representing Colorado’s thriving Bioscience Industry,” Eder said.
In the bioscience space, Primavera has worked with CBSA member company, Sharklet Technologies, for the past seven years, achieving key media placements internationally, nationally and locally for the Colorado-based medical technology company. Most notably Primavera has placed Sharklet on a PBS Nova segment, CBS News Sunday Morning, The Wall Street Journal, Fast Company, Wired, Discover Magazine, Inc Magazine, Popular Science, FierceBiotech, European Medical Device Manufacturer, the Discovery Channel and, the Jeopardy game show where Sharklet was included as a featured answer. For more information, visit http://sharklet.com/about-us/in-the-news and www.theprimaveragroup.com.
“I’ve worked with Sarah over the years and I’m simply thrilled to be able to pass CBSA’s PR baton to her and her team. I’m confident Sarah’s business and PR acumen is exactly what CBSA needs to take our organization to the next level in its awareness growth curve. While I’m retiring as CBSA’s PR consultant, I’m only semi-retiring from the PR business. I’ll continue to keep my Absolutely PR consulting firm open in the future, but will be taking on projects of a lesser scope than the CBSA contract to allow for more travel and time with my family,” Holben explains. For more information, visit: http://www.absolutelypr.com.
Colorado attained a number of key financings, acquisitions and expansions in its bioscience industry during 2014. April Giles, President and CEO of the Colorado BioScience Association says: "We’ve seen a number of exciting deals come to fruition in our Colorado bioscience community during 2014, which strengthens our state’s position as a national industry leader. We’re thrilled that CBSA has continued to play a significant role in promoting Colorado as a dynamic region for bioscience innovation and investment.”
Highlighted Financings and Acquisitions in 2014 Include: * Terumo BCT broke ground on a 120,000-square-foot global headquarters building – April 1, 2014
Terumo BCT is building a 120,000-square-foot Global Headquarters building on its Lakewood campus. In 2015,
when the building opens, Terumo BCT will occupy 90,000 square feet, leaving the additional space available for future growth and development. When complete, it will accommodate an estimated 400 associates. http://coloradocommunitymedia.com/stories/A-global-home,151084
* BioScience Park Center 2 groundbreaking adding 112,000 square foot building – April 4, 2014
The Fitzsimons Redevelopment Authority (FRA) and CU's Bioengineering program, design a multipurpose building for education, research and clinical care, with an added entrepreneurial element of private biosciences companies. Bioengineering students will have classes on the first two floors of the four-story building, and from there, the students will move up a floor and practice what they have learned and then move up again to begin their own commercial bioscience company on the top floor. http://www.ucdenver.edu/about/newsroom/newsreleases/Pages/Bioscience-2-groundbreaking-April-2014.aspx
* Clovis Oncology to offer $200M in convertible senior notes in private placement to investors – Sept 3, 2014
Boulder based Clovis Oncology Inc. announced it intended to offer $200 million aggregate principal amount of its convertible senior notes due 2021 in a private placement to qualified international buyers.
* InDevR Wins $14.7M Barda Contract for Cutting-Edge Influenza Diagnostic – September 15, 2014
Boulder based InDevR announced that it signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to complete product development of their unique influenza diagnostic, FluChip-8G, which is capable of rapidly genotyping influenza viruses directly from clinical samples. http://www.marketwired.com/press-release/-1947252.htm
* N30 Pharmaceuticals Secures $30 Million in Oversubscribed Crossover Financing – November 19, 2014
Boulder based N30 Pharmaceuticals, Inc. (“N30 Pharma”), a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis (CF), has raised $30 million in a mezzanine round of financing. Proceeds from the financing will primarily be used to advance the Company’s clinical trial program. New investors include Wellington Management, RA Capital Management, LLC, Jennison Associates LLC (on behalf of certain clients), Rock Springs Capital Management LP, and Sabby Management, LLC, who joined existing investor, Deerfield Management Company. http://www.prnewswire.com/news-releases/n30-pharmaceuticals-secures-30-million-in-oversubscribed-crossover-financing-283193921.html
"The Colorado Institute for Drug, Device and Diagnostic Development (CID4) has begun a search for a new Executive Director, as Kevin M. Smith leaves as part of a planned retirement." Link to BioPortfolio
"Kevin M. Smith will step down from his position as president and chief executive of the Colorado Institute for Drug, Device and Diagnostic Development, also known as CID4, on Dec. 31. The nonprofit bioscience charity has formed a search committee to find a new CEO, CID4 board Chairman Steve Orndorff said. Smith will be available through February to assist during the transition." Link to BizWest
Quoting from today's Denver Business Journal posting by Greg Avery:
"The Colorado Institute for Drug, Device and Diagnostic Development is looking for a new CEO in advance of the retirement of Kevin Smith, the nonprofit group's current leader.
Smith is a co-founding executive of the Aurora-based nonprofit, known as CID4, that was started to help fill a gap in funding for bioscience startups. CID4 identifies and helps fund early-stage Colorado bioscience companies that have the potential to grow and create local jobs.
Smith, a former president of Gambro U.S.A., a Lakewood-based medical device company, plans to retire Dec. 31. He'll be available to the organization through February to help in the transition, the organization said.
The CID4 board has formed a CEO search committee."
"Kevin M. Smith, president and CEO of the Colorado Institute for Drug, Device and Diagnostic Development (CID4) since 2010, will retire from his post on Dec. 31.
Steve Orndorff, chairman of the CID4 board and president and CEO of Micobiome Therapeutics, said the board has formed a search committee and that Smith will remain available through February 2015 to assist in a smooth transition for CID4’s new executive director...
...CID4 said all inquiries should be directed to the CID4 Search Committee at email@example.com. Deadline to apply is Dec. 20."
"Kevin M. Smith, President and CEO of the Colorado Institute for Drug, Device and Diagnostic Development (CID4) since 2010, will retire from his position as Chief Executive Officer on December 31, 2014. The announcement is made by Steve Orndorff, PhD, Chairman of the CID4 Board and President & CEO of MicroBiome Therapeutics, who says the CID4 Board has formed a search committee and that Smith will be available through February 2015 to assist in a smooth transition for the new Executive Director."
Kevin M. Smith to Retire as President & CEO of the Colorado Institute for Drug, Device and Diagnostic Development; Search Committee Formed to Hire Smith’s Successor
The Colorado Institute for Drug, Device and Diagnostic Development (CID4) has begun a search for a new Executive Director, as Kevin M. Smith leaves as part of a planned retirement. Mr. Smith will remain with CID4 through February 2015 to ensure a smooth and successful transition for CID4’s new leader. Aurora, CO November 24, 2014 – Kevin M. Smith, President and CEO of the Colorado Institute for Drug, Device and Diagnostic Development (CID4) since 2010, will retire from his position as Chief Executive Officer on December 31, 2014. The announcement is made by Steve Orndorff, PhD, Chairman of the CID4 Board and President & CEO of MicroBiome Therapeutics, who says the CID4 Board has formed a search committee and that Smith will be available through February 2015 to assist in a smooth transition for the new Executive Director.
“With the ongoing changes in the healthcare and life science sectors, CID4 is revisiting how it can best support our industry,” Orndorff said. “CID4 is well positioned for its future and we believe the new Executive Director position will strengthen our alignment with the State of Colorado in our mutual quest to create new jobs and business opportunities within the dynamic life science sector of advanced industries.”
All inquiries should be directed to the ‘CID4 Search Committee’ at firstname.lastname@example.org. The deadline for applications is December 20, 2014. Principals only need apply, please.
About Kevin M. Smith, CID4 President/CEO
Smith was part of the team that founded CID4 in 2009. Prior to CID4, Smith was President of Gambro, Inc., the U.S. holding company for Gambro AB, the Sweden-based medical device and healthcare services company. He started his career with Arthur Young in New York and was a partner with Ernst & Young, leading the development of their Colorado life science practice at the time he left to join Gambro.
“While I will no longer be leading CID4, I will stay active in the Colorado life science community through my Board responsibilities at the Colorado BioScience Association, Donor Alliance and AlloSource, my service on the Centura Health Audit and Corporate Responsibility Committee and my investment activities at KMG Capital Partners LLC,” Smith said. “CID4’s success is grounded in the excellent technologies that are being developed in Colorado. We have invested approximately $3 million into nine early stage companies. Those firms have gone on to create 85 new jobs and raise an additional $30 million to support the commercialization of their patient-focused technologies. I am proud to have played a role in this process.”
About the Colorado Institute for Drug, Device and Diagnostic Development
Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visit http://CID4.com.
Kevin M. Smith, President/CEO CID4, http://CID4.com - email@example.com, (720) 859-4047
"Colorado bioscience’s best: The Colorado BioScience Association also honored their industry’s leaders this week.
AlloSource, which is a nonprofit organization based in Centennial, was named company of the year by the association.
AlloSource develops and distributes tissues that can be used in surgical procedures such as skin grafts and joint repair. It has more than 400 employees.
This year, AlloSource expanded its work in stem cell research and began using microbe detection technology developed by NASA’s Jet Propulsion Laboratory to improve tissue decontamination procedures. AlloSource’s hope is that the NASA technology will cut the time it takes to get donated tissue and organs to recipients.
Boulder-based ViroCyt won the award for rising star of the year. The company’s Virus Counter is able to calculate a virus’ growth rate in minutes and is used in vaccine and drug development, viral therapeutics, and protein expression research.
Colorado BioScience Association (CBSA) announced winners of its 11th annual industry awards at the Marriott City Center, Denver, on November 6. The announcement is made by April Giles, CBSA President and CEO, who opened the evening with an overview of this year’s industry accomplishments.
Giles was joined by 850 KOA’s Steffan Tubbs and CBSA Board Chair Derek Cole, announcing the following winners:
Company of the Year: AlloSource
AlloSource, based in Centennial, is committed to its success and growth in Colorado’s bioscience community. Expanding its Colorado headquarters by 90,000 square feet in 2012, the company continued the momentum in 2013 by launching a new proprietary allograft used in a broad range of soft tissue surgical procedures. Most recently in 2014, AlloSource announced two new partnerships which will expand their work in stem cell innovation as well as undertake a new project with NASA through the Space Act Agreement. This work will advance microbial research in tissue processing for various Mars missions. Visit: http://www.allosource.org . Finalists for Company of the Year were: Mountainside Medical, Boulder, http://mountainsidemed.com and Spectranetics, Colorado Springs, http://www.spectranetics.com.
Rising Star of the Year: ViroCyt
ViroCyt, Boulder, launched the first Virus Counter in 2011, which has proven to be faster, more accurate and cost effective than traditional viral quantification methods with results in minutes instead of days or weeks. This year ViroCyt announced the introduction of the next generation Virus Counter at the World Vaccine Congress held in Washington, DC. The technology has already been adopted by the leading companies in the fields of viral vaccine development and therapeutic protein expression. Virocyt’s innovations are changing the landscape of virus detection technologies. Visit: http://virocyt.com. Finalists for Rising Star were: JustRight Surgical, Boulder, http://www.justrightsurgical.com and Silvergate Pharmaceuticals, Greenwood Village, http://www.silvergatepharma.com.
Lifetime Achievement: Dr. Richard Duke
Dr. Duke is an accomplished scientist with over 25 years of experience in cutting-edge biomedical research, and is a tenured faculty member in the Departments of Medicine and Immunology at the University of Colorado Denver. He has been instrumental in the development of Colorado’s bioscience industry as an executive, inventor, biomedical researcher and serial entrepreneur. Dr. Duke was involved in the formation and management of GlobeImmune, Newellink USA, ApopLogic Pharmaceuticals, Sierra Neuropharmaceuticals, PeptiVir, MenoGeniX and Aurora Oncology. He has also been integral to these Colorado-based companies, by raising more than $200 million in financing and helped bring multiple products to human clinical trials.
One of the Colorado bioscience industry’s proudest achievements was the creation of the BioScience Discovery Evaluation Grant Program (also referred to as BDEG). Dr. Duke was the visionary and driving force behind the development of BDEG, making the program what it is today. This initial concept in 2006 has now become a national model for state’s trying to cultivate a bioscience industry of their own.
Institute Leadership: Jim Rosa
During last year’s Awards Dinner, CBSA introduced a new award, the Institute Leadership award. This award was created to recognize outstanding efforts that further the Colorado Bioscience Institute’s mission of providing education, workforce and career development for life science professionals, companies, students and teachers. This year, CBSA honors one outstanding Institute champion, Jim Rosa, for his leadership on the workforce training programs. The workforce training programs involve partners with deep content expertise and a strong commitment to advancing knowledge and closing workforce gaps in Colorado’s bioscience eco-system.
Business Partner of the Year: Phyllis Arthur, BIO
CBSA’s 2014 Business Partner of the Year is Phyllis Arthur, Senior Director of Vaccines, Immunotherapeutics and Diagnostics Policy at the Biotechnology Industry Organization. Ms. Arthur was a remarkable partner for CBSA on Senate Bill 222, becoming the bioscience industry’s taskforce representative and also forging lasting relationships with the Colorado Department of Public Health and Environment, the Colorado Children's Immunization Coalition and many other stakeholders. In the end, the taskforce collectively - and unanimously – agreed to all of the recommendations for Colorado. Phyllis continues to remain involved during the implementation phase and will act as a resource providing national best practice models and allowing the State to leverage her relationships and knowledge base.
Educator of the Year: Deborah Carnevale
Deborah Carnevale is the Director of the Overland High School Biotechnology Program. Under her leadership, the school’s biotechnology program has received multiple grants and certifications. Students who have completed the program have an advantage when entering college. Their advanced research skills in biotechnology has enabled many of them to receive laboratory jobs as university freshmen, a rare opportunity. Her dedication and commitment to her students is commendable.
Volunteer of the Year: Amy Wedeking Shannon
Ms. Shannon is Principal Consultant for Caliber One Solutions and an active participant on CBSA’s Membership Committee. Her knowledge base and relationships in the community have proven to be very valuable to the membership efforts of CBSA. Her drive is tireless and capable when bringing new members into the organization. Amy also provides great leadership and insight through her recommendations to better the committee process. In the words of Committee Chair (and 2013 Volunteer of the Year) Dustin Whistler, the committee is very lucky to have her.
Chairman’s Award: Monisha Merchant
Monisha Merchant serves as Senior Policy Advisor to Senator Michael Bennet and has been a tremendous leader for the bioscience industry and the State as a whole. During the development of the 2011 America Invents Act, Senator Bennet co-authored a provision to establish three United States Satellite Patent and Trademark Offices. Ms. Merchant’s commitment to the goal of securing a satellite office in Colorado was truly commendable. She helped to spearhead the process and forged an incredible coalition of public and private partners which ultimately led to the selection of the Denver site. This achievement will not only better the entrepreneurs in the state and also across the region. Ms. Merchant also played an integral role in leveraging her influence and relationships to create the Blackstone Entrepreneurial Network (BEN) in Colorado. BEN links Master Entrepreneurs across industries and regions to support high growth entrepreneurial activities. Most recently, she facilitated the “Bioscience in Colorado” day where she and Senator Bennet invited key community leaders to explore the industry’s eco-system.
About the Awards Dinner
The Awards Dinner began with a cocktail reception followed by dinner and the awards program. In addition, the Boettcher Foundation presented its 2014 Class of Boettcher Investigators in the Webb-Waring Biomedical Research Program. The event closed with a keynote address by Olympic cycling medalist and Parkinson’s survivor Davis Phinney.
Phinney, diagnosed with Parkinson’s disease in 2000 at the age of 40, founded the Boulder-based Davis Phinney Foundation in 2004. Today, Phinney is both a role model in the cycling community and an inspiration to the estimated 1.5 million Americans and estimated 10 million worldwide who are currently living with the disease. Tens of thousands of people living with this disease have been directly touched by one of the Davis Phinney Foundation programs or through Davis Phinney’s inspirational message: “it is possible to live well with Parkinson’s today.” For more information, visit: http://www.davisphinneyfoundation.org and http://www.medtronicdbs.com/parkinsons/personal-stories/davis-phinney/index.htm.
Sponsors of the Awards Dinner included: Boettcher Foundation; Cooley, LLP; Fisher Scientific, Fitzsimons Redevelopment Authority, Medtronic and Terumo BCT.
CBSA will host its Annual Awards Dinner on November 6 at the Denver Marriott City Center. The announcement is made by April Giles, CBSA President and CEO, who says, “We are thrilled to again celebrate the success of Colorado’s bioscience industry and recognize those standout companies and individuals who have contributed significantly to the growth of our community this year. Further, we are fortunate to welcome Olympic medalist and cycling great Davis Phinney as our keynote speaker for the event.”
Phinney, diagnosed with Parkinson’s disease in 2000 at the age of 40, founded the Davis Phinney Foundation in 2004; a national organization, based in Boulder, CO. Today, Phinney is both a role model in the cycling community and an inspiration to the estimated 1.5 million Americans and 10 million worldwide who are currently living with the disease. Tens of thousands of people living with this disease have been directly touched by one of the Davis Phinney Foundation programs or through Davis Phinney’s inspirational message: “it is possible to live well with Parkinson’s today.” For more information, visit: http://www.davisphinneyfoundation.org.
In 2009, it was announced that Phinney’s foundation had joined forces with Medtronic, Inc. (one of the sponsors of the CBSA Awards Dinner) to raise awareness among individuals with Parkinson's disease and their caregivers about how to improve their lives today. Together, through educational programs focused on daily victories over Parkinson’s disease, they aim to increase understanding about the importance of exercise, living a healthy lifestyle and the consideration of various treatment options. Phinney has found relief from debilitating tremors and stiff limbs and joints after receiving Medtronic Deep Brain Stimulation (DBS) Therapy. For more information about Phinney’s experience with DBS, visit: http://www.medtronicdbs.com/parkinsons/personal-stories/davis-phinney/index.htm.
The Awards Dinner, emceed by 850 KOA Morning News Anchor Steffan Tubbs, will begin with a cocktail reception followed by dinner and a dynamic program. CBSA will first recognize those companies and individuals who are making a significant difference in Colorado’s vibrant bioscience industry. The Boettcher Foundation will then present the 2014 Class of Boettcher Investigators in the Webb-Waring Biomedical Research Program. The event closes with Phinney’s keynote.
This year’s Bioscience Industry Awards include:
* Lifetime Achievement
* Company of the Year
* Rising Star
* Institute Leadership
* Business Partner of the Year
* Educator of the Year
* Volunteer of the Year
* Chairman’s Award
Tickets for the Awards Dinner are available for purchase at the CBSA website. Individual tickets are $150. Tables (8 seats) are available for $1,250 for CBSA members and $1,500 for non-CBSA members. Please note: the Awards Dinner was a sellout event last year, so do not delay securing arrangements. Visit: http://www.cobioscience.com/events-calendar/awards-dinner-2014.
Sponsorships for the Awards Dinner are also still available. Those interested in sponsorships should contact Tracey Nilson at firstname.lastname@example.org no later than October 24. Sponsors, as of the date of this release, include: Boettcher Foundation; Cooley, LLP; Fisher Scientific, Fitzsimons Redevelopment Authority, Medtronic and Terumo BCT.
"The Colorado Institute for Drug, Device and Diagnostic Development (CID4) announced it is awarding $200,000 to Denver-based Sapphire Technology for funding and management assistance in developing its proprietary dental instruments.
Unlike current dental filling instruments, which typically use metal for their tips, Sapphire's SGS instrument line will employ highly polished and optically clear sapphire tips instead. The use of sapphire is intended to significantly reduce composite pullback as experienced with current metal instruments, which in turn is expected to provide a reduction of voids in the composite material and improve the bond between the filling material and the patient's natural tooth, according to the company."
"Your dental visit may soon have a lot more bling.
Denver-based Sapphire Technology LLC on Tuesday was awarded $200,000 from the Colorado Institute for Drug, Device and Diagnostic Development, or CID4, for continued development of its dental instruments made with sapphires.
Sapphire, which is a gemstone variety of corundum, ranks at the top of the Mohs scale of mineral hardness — the universal standard to measure the hardness of gemstones and minerals.
The gemstone has been in the news recently amid speculation that Apple might use highly scratch-resistant glass made of sapphires for its new iPhone screens.
"The Colorado Institute for Drug, Device and Diagnostic Development (CID4) awarded $200,000 to Denver-based Sapphire Technology LLC to develop the company’s proprietary dental instruments.
Sapphire is a development-stage dental device company advancing proprietary sapphire-tipped instruments for use in dental procedures involving photo-cured, resin composite filling and restoration materials.
'We are extremely excited about our investment and involvement in Sapphire Technology,' said Kevin Smith, CID4 president and CEO."
The Colorado Institute for Drug, Device and Diagnostic Development (CID4), is awarding $200,000 to Denver-based Sapphire Technology, LLC, for funding and management assistance in developing its proprietary dental instruments. The announcement is made by Kevin M. Smith, CID4 President and CEO, who says, “Sapphire Technology is a development-stage dental device company, advancing its proprietary sapphire-tipped instruments for use in dental procedures involving photo-cured resin composite filling and restoration materials.”
As part of CID4’s management support, Jonathan Thorne, a member of the CID4 Board for the past two years, will join Sapphire Technology’s Founder Alan Wong, DDS, and CEO H. Steven Rosen on the Company’s Board of Managers.
“We are extremely excited about our investment and involvement in Sapphire Technology,” Smith said. “Not only will Sapphire Technology’s proprietary devices address a recognized problem in the dental instrument market as the movement toward composite filling and restoration materials continues to grow, but Sapphire Technology’s use of Colorado-based contract manufacturers should contribute significantly to the advancement of the State’s life science industry.”
Unlike current dental filling instruments, which typically utilize metal for their tips, Sapphire Technology’s SGS® instrument line will employ highly polished and optically clear sapphire tips instead. The use of sapphire is intended to significantly reduce composite pullback as experienced with current metal instruments, which in turn is expected to provide a reduction of voids in the composite material and improve the bond between the filling material and the patient’s natural tooth. Voids and poor bonds in dental fillings can trap bacteria, provide opportunity for further tooth decay, and provide micro-leakage pathways for post-filling hot and cold sensitivity issues.
dBMEDx (Littleton) won the 2014 Venture Showcase competition at the BioWest Conference and Expo yesterday at the Marriott City Center Denver, receiving the $7,500 cash prize. The announcement is made by April Giles, Colorado BioScience Association (CBSA) President and CEO who says, “We are very proud to announce dBMEDx as the winner of the Venture Showcase. The check presentation was an exciting end to the BioWest Conference. The award not only includes the cash prize of $7,500 but also includes recognition and exposure for the company. ” This award is sponsored by Dorsey and Whitney LLP and The Metro Denver Economic Development Corporation. BioWest, the Rocky Mountain Region's premier medical device and biotechnology conference, is organized by the CBSA and held every other year.
dBMEDx is a Colorado-based medical device development company that is creating clinical decision and patient monitoring devices using its patented, non-invasive scanning technology. These devices combine the power and safety of ultrasound with sophisticated image processing electronics and software to provide simple, fully automated and completely noninvasive diagnostic measurements. Fully automated means that very little training is required and the user does not need any experience with ultrasound to use our devices. To enable this level of automation, dBMEDx has successfully created and patented an extremely compact, wireless, 3D scan engine.
The scan engine, which can be held in the palm of the hand, includes a complete 3D ultrasound imaging machine and automated image processor within a small, sealed tube. The system also includes an integrated Bluetooth radio and rechargeable battery, which is inductively charged. The company is in the process of commercializing the first application for this technology, the BBS Revolution™ device for automated bladder volume measurement, and has a range of pipeline of products for other clinical applications as well. Visit: http://www.dbmedx.com. Video of winning Venture Showcase pitch by dBMEDx CEO David Shine:
The Venture Showcase format allowed each company’s lead executive to make a 15-minute presentation with an accompanying slide deck explaining their technology and business plan to a panel of judges in front of a live audience. This year's judging panel included the following:
• Michael Weiner, Partner, Dorsey
• Ned Scheetz, Managing Director, Aphelion Capital
• Steve VanNurden, President and CEO, Fitzsimons Redevelopment Authority
The three 2014 Venture Showcase finalists included:
The BioWest Conference was attended by more than 300 industry leaders, government representatives, executives, researchers, investors and entrepreneurs. “We look forward to the continued growth of the bioscience industry and presenting the conference in again 2016,” Giles concludes.
September 10, at the Marriott City Center, Denver:
Exhibitors will be showcasing up to 40 new technologies, products and services at the 2014 BioWest Conference and Expo, the Rocky Mountain Region’s premier medical device and biotechnology conference organized by the Colorado BioScience Association (CBSA).
The announcement is made by CBSA President and CEO April Giles, who says: “The 2014 BioWest Conference and Expo has an amazing line up of keynotes, CEO presentations and offers a wide variety of products and services on display in the Expo Hall. This year, the Expo Hall will have added energy and excitement with the C-Level Unplugged interviews on center stage and the Venture Showcase winner announcement and check presentation.”
The BioWest Conference is a one-day event attended by more than 300 industry leaders, government representatives, executives, researchers, investors and entrepreneurs. The conference features keynote speakers Margaret A. Hamburg, M.D., Commissioner of the U.S. Food and Drug Administration and keynote panelists; Jandel Akeynote llen-Davis, M.D., Vice President, Government and External Relations, Kaiser Permanente Colorado; James Hill, Ph.D. is Professor of Pediatrics and Medicine at the University of Colorado School of Medicine; Len Tacconi, President, HMR Weight Management Services Corp., a subsidiary of Merck and Co. Inc., moderated by Steve VanNurden, President and CEO, Fitzsimons Redevelopment Authority; and Russell Slifer, Director, United States Patent and Trademark, Rocky Mountain Regional Office.
Additional Program Segments include:
* C-Level Unplugged: Conversation with Top Level Leadership.
* Colorado Companies: From Concept to Market featuring three of Colorado’s Top BioScience CEOs (pictured above: Bill Aldrich, EndoShape; David Brunel, Biodesix; and Byron Hewett, SomaLogic).
* BioTalks: Big Bold Innovative Ideas.
* Venture Showcase: Three emerging life science companies present to a panel of investors for a $7,500 Venture Showcase cash prize. Finalists include: dBMEDx, Littleton; KromaTiD, Inc., Fort Collins; Mighty Oak Medical, Englewood.
More About BioWest 2014 | September 10, 2014 | #BioWest2014
Conference Registration is now open at http://www.CoBioScience.com/BioWest. Rates for members start at $325 and $375 for non-members and passes for the expo hall and reception only are $125 for members and $150 for non-members. Group rates are available for companies and organizations. Conference Sponsors include: AdvaMed, Amgen, BIO, BioFrontiers Institute, DePuy Synthes, DaVita Clinical Research, Dorsey and Whitney LLP, Dohmen Life Science Services, EY, Evergreen Research, Fitzsimons Redevelopment Authority, Fisher Scientific, Metro Denver EDC, The Mead Consulting Group, Quintiles, SomaLogic, Sheridan Ross PC, Square 1 Bank, Silicon Valley Bank, TerumoBCT.